- Home
- IFRX vs SRFM Comparison
IFRX vs SRFM Comparison
Compare IFRX & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- SRFM
- Stock Information
- Founded
- IFRX 2007
- SRFM 2011
- Country
- IFRX Germany
- SRFM United States
- Employees
- IFRX N/A
- SRFM N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- IFRX Health Care
- SRFM Consumer Discretionary
- Exchange
- IFRX Nasdaq
- SRFM Nasdaq
- Market Cap
- IFRX 65.8M
- SRFM 58.2M
- IPO Year
- IFRX 2017
- SRFM 2023
- Fundamental
- Price
- IFRX $1.30
- SRFM $2.56
- Analyst Decision
- IFRX Strong Buy
- SRFM Strong Buy
- Analyst Count
- IFRX 2
- SRFM 3
- Target Price
- IFRX $9.00
- SRFM $6.02
- AVG Volume (30 Days)
- IFRX 322.6K
- SRFM 193.1K
- Earning Date
- IFRX 05-07-2025
- SRFM 05-13-2025
- Dividend Yield
- IFRX N/A
- SRFM N/A
- EPS Growth
- IFRX N/A
- SRFM N/A
- EPS
- IFRX N/A
- SRFM N/A
- Revenue
- IFRX $171,642.00
- SRFM $119,425,000.00
- Revenue This Year
- IFRX $106.72
- SRFM N/A
- Revenue Next Year
- IFRX $66.89
- SRFM $45.73
- P/E Ratio
- IFRX N/A
- SRFM N/A
- Revenue Growth
- IFRX 162.79
- SRFM 97.38
- 52 Week Low
- IFRX $0.82
- SRFM $0.90
- 52 Week High
- IFRX $2.82
- SRFM $6.72
- Technical
- Relative Strength Index (RSI)
- IFRX 58.32
- SRFM 44.19
- Support Level
- IFRX $0.82
- SRFM $2.32
- Resistance Level
- IFRX $1.12
- SRFM $2.50
- Average True Range (ATR)
- IFRX 0.13
- SRFM 0.24
- MACD
- IFRX 0.06
- SRFM 0.06
- Stochastic Oscillator
- IFRX 90.49
- SRFM 88.11
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.